Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
FMR LLC and related reporting person Abigail P. Johnson report beneficial ownership of common stock of Shoulder Innovations Inc. FMR LLC reports beneficial ownership of 3,673,960 shares of common stock, representing 17.7% of the class, with 3,655,660 shares subject to sole voting power and 3,673,960 shares subject to sole dispositive power.
Abigail P. Johnson reports beneficial ownership of 3,673,960 shares with sole dispositive power but no sole or shared voting power, reflecting her position as a control person of FMR LLC. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than 5% of the total outstanding common stock.
Gilde Healthcare Holding B.V., a ten percent owner of Shoulder Innovations, reported indirect sales of 110,563 shares of common stock through Cooperatieve Gilde Healthcare V U.A. on August 3–4, 2026 at weighted average prices of $22.71 and $22.77 per share.
Gilde Healthcare Holding B.V., a 10% shareholder of Shoulder Innovations, sold 48,279 shares of common stock on July 30–31, 2026 in indirect open‑market transactions at weighted‑average prices of $23.36 and $22.73 per share, within the disclosed intraday ranges. The shares are held through Coöperatieve Gilde Healthcare V U.A. and related entities, and a Gilde partner disclaims beneficial ownership beyond any pecuniary interest; the trades were not reported under a Rule 10b5‑1 plan.
A selling security holder plans to dispose of 200,000 shares of common stock of the issuer through transactions on the NYSE, with an indicated aggregate market value of $4,850,000.00. The shares are proposed to be sold beginning on 07/29/2026, with 20,738,226 shares of common stock stated as outstanding.
The shares to be sold were acquired in several transactions, including private placements of Series D and Series E convertible preferred stock on 02/10/2023 and 03/06/2025, respectively, which converted into common stock upon the IPO closing on 08/01/2025, with the holding period tacking under Rule 144(d)(3)(ii). An additional 100,000 shares were purchased in the issuer’s registered IPO on 08/01/2025 at $15.00 per share as control securities.
Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.
Shoulder Innovations, Inc. director and 10% owner Casey M. Tansey reported an equity award and updated holdings. He received a grant of 5,046 restricted stock units (RSUs) of common stock at $0.00 per share, increasing his directly held shares to 52,712 after the award.
The RSUs vest on the earlier of the company’s 2027 annual stockholder meeting or June 26, 2027, with each RSU delivering one common share. Tansey elected to defer settlement of these RSUs until his departure from the Board. Additional common stock is held indirectly through U.S. Venture Partners funds and related Presidio Management Group entities, where Tansey may share voting and dispositive power but beneficial ownership is disclaimed except for any pecuniary interest.
Sidow Kevin K. reported acquisition or exercise transactions in this Form 4 filing.
SHOULDER INNOVATIONS, INC. director Kevin K. Sidow received an equity grant of 5,046 restricted stock units (RSUs), each representing one future share of common stock at no purchase price. These RSUs vest on the earlier of the 2027 annual stockholder meeting or June 26, 2027.
Sidow has voluntarily elected to defer receipt of the underlying common shares until he leaves the Board of Directors. After this award, his reported direct holdings total 25,056 shares or share-equivalent units.
Shoulder Innovations director Andrew Hykes received an equity award in the form of restricted stock units (RSUs). The filing reports a grant of 5,046 RSUs of Common Stock at no cash cost, increasing his directly held shares to 6,769 following the award.
The RSUs will vest on the earlier of the 2027 annual stockholders meeting or June 26, 2027, and each RSU converts into one share of Common Stock. Hykes has elected to defer receipt of the shares until his departure from the Board of Directors. His reported holdings include 1,723 shares received as an in-kind distribution from Gilmartin Capital Fund I, LP, which were previously not reported as beneficially owned.
Shoulder Innovations, Inc. director Paul Buckman reported receiving an award of 5,046 restricted stock units (RSUs) of Common Stock. The RSUs will vest on the earlier of the company’s 2027 annual stockholders’ meeting or June 26, 2027, and each RSU converts into one share. Buckman has elected to defer receiving the underlying shares until he leaves the Board of Directors. Following this grant, he holds 63,750 shares of Common Stock directly.
Buchholz Richard reported acquisition or exercise transactions in this Form 4 filing.
SHOULDER INNOVATIONS, INC. director Richard Buchholz reported an equity compensation grant in the form of restricted stock units (RSUs). He was awarded 5,046 RSUs, each representing a contingent right to receive one share of common stock at no cash cost.
The RSUs will vest on the earlier of the company’s annual meeting of stockholders to be held in 2027 or June 26, 2027. Following this grant, Buchholz’s reported direct holdings total 18,712 shares of common stock, reflecting a routine, compensation-related increase in his equity stake.
Shoulder Innovations entered a new Loan and Security Agreement with Stifel Bank that provides up to $50 million of senior secured financing. It includes a fully funded $15 million growth capital term loan and a $30 million asset-based revolving line of credit, with an additional $5 million available subject to conditions.
The term loan proceeds were used to repay and terminate the prior Trinity Capital facility, including $15.7 million of principal, interest and premiums, releasing Trinity’s security interests. The new term loan bears interest at the greater of 0.75% below prime or 5.00%, is interest-only through June 30, 2029, and matures in June 2031.
The revolving facility, which was undrawn at closing, bears interest at the greater of the prime rate or 5.00%, matures in June 2029, and is secured by substantially all company assets other than specified intellectual property. The agreement includes customary covenants and a springing minimum revenue test tied to total debt and liquidity.